Health insurers will not be covering the cost of a new obesity medication coming on to the market in Ireland. Mounjaro, a ...

As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

Earnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

A broad measure of Asian equities slipped, pressured by sell-offs in Hong Kong and mainland China. Futures for the S&P 500 ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...